pocketful logo light
pocketful logo light
Epigral Ltd logo

Epigral Ltd

NSE: EPIGRAL BSE: 543332

₹1084.10

(2.61%)

Sun, 05 Jul 2026, 01:06 am

Epigral Price to Sales Ratio (P/S)

Particulars2018201920202021202220232024
Price to earnings ratio00016.0111.0923.2522.42
Price to book ratio0005.573.673.634.30
Price to sales ratio0002.611.812.403.19
Price to cash flow ratio00017.146.9213.9821.39
Enterprise value0005014Cr4783Cr5511Cr8513Cr
Enterprise value to EBITDA ratio0009.777.0612.0712.40
Debt to equity ratio0.790.910.791.370.820.770.31
Return on equity %021.1415.8835.8539.3616.8622.65

Epigral Ltd Price to Sales Ratio

The Epigral Ltd Price to Sales Ratio is a key financial metric used by investors to evaluate Epigral Ltd's valuation, profitability, and overall financial performance. Tracking the Epigral Ltd Price to Sales Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.

Epigral Ltd (NSE: EPIGRAL, BSE: 543332) is currently trading at ₹1084.10, with a market capitalization of ₹4802.06Cr. As a leading company in the Process industries sector and Chemicals: agricultural industry, monitoring the Epigral Ltd Price to Sales Ratio is essential for fundamental analysis.

Epigral Ltd Price to Sales Ratio Current Value

The current Epigral Ltd Price to Sales Ratio stands at 3.19.

The latest Epigral Ltd Price to Sales Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.

Epigral Ltd Price to Sales Ratio Historical Trend

The Epigral Ltd Price to Sales Ratio has shown the following historical trend:

  • 2024: 3.19
  • 2023: 2.40
  • 2022: 1.81
  • 2021: 2.61
  • 2020: 0

The recent rise in Epigral Ltd Price to Sales Ratio suggests strengthening valuation trends and improving market sentiment.

What Epigral Ltd Price to Sales Ratio Indicates for Investors

The Epigral Ltd Price to Sales Ratio plays a crucial role in understanding the company's financial health and valuation.

The P/S ratio helps evaluate valuation relative to company revenue.

Epigral Ltd Price to Sales Ratio Analysis Summary

The Epigral Ltd Price to Sales Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Epigral Ltd Price to Sales Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.

Regular tracking of Epigral Ltd Price to Sales Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.

Open Your Free Demat Account

Enter your phone number